|Bid||15.35 x 900|
|Ask||15.78 x 800|
|Day's range||15.28 - 15.70|
|52-week range||11.22 - 29.65|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||88.31|
|Earnings date||10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.33|
Cara Therapeutics (NASDAQ: CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. Another biotech had some good news on the FDA front: Cara Therapeutics, ticker there is CARA, and its partner Vifor Pharma (OTC: GNHAY) announced on Monday that the FDA had approved Korsuva for trading moderate to severe pruritus associated with chronic kidney disease, and this is in adults undergoing dialysis.
Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.